NCT05072106 2025-09-16
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
Clinical Trials
11 trialsNCT05063318 2025-09-02
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT04638491 2024-06-10
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Luye Pharma Group Ltd.
Phase 1 Completed
NCT01831089 2020-04-10
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT01970540 2020-03-09
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
PharmaMar
Phase 1 Completed
NCT01980667 2017-01-26
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
PharmaMar
Phase 1 Completed
NCT02210364 2016-12-14
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
PharmaMar
Phase 1 Completed
NCT01405391 2016-01-15
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
PharmaMar
Phase 1 Completed
NCT01314599 2015-11-05
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
PharmaMar
Phase 1 Completed
NCT00877474 2015-11-04
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT01970553 2015-04-01
Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
PharmaMar
Phase 1 Completed